Skip to main content

Incidence of statin use in older adults with and without cardiovascular disease and diabetes mellitus, January 2008- March 2018.

Publication ,  Journal Article
Panozzo, CA; Curtis, LH; Marshall, J; Fine, L; Wells, BL; Brown, JS; Haynes, K; Pawloski, PA; Hernandez, AF; Malek, S; Syat, B; Platt, R
Published in: PLoS One
2019

BACKGROUND: Data from randomized controlled trials and observational studies on older adults who take statins for primary prevention of atherosclerotic cardiovascular disease are limited. To determine the incidence of statin use in older adults with and without cardiovascular disease (CVD) and/or diabetes (DM), we conducted a descriptive observational study. METHODS: The cohort consisted of health plan members in the NIH Collaboratory Distributed Research Network aged >75 years who had continuous drug and medical benefits for ≥183 days during the study period, January 1, 2008- March 31, 2018. We defined DM and CVD using diagnosis codes, and identified statins using dispensing data. Statin use was considered incident if a member had no evidence of statin exposure in the claims during the previous 183 days, and the use was considered long-term if statins were supplied for ≥180 days. Incidence rates were reported among members with and without CVD and/or diabetes, and stratified by year, sex, and age group. RESULTS: Among 757,569 eligible members, 109,306 older adults initiated statins and 54,624 became long-term users. Health plan members with CVD had the highest incidence of statin use (143.9 initiators per 1,000 member-years for CVD & DM; 114.5 initiators per 1,000 member-years for CVD & No DM). Among health plan members without CVD, those with DM had rates of statin use that were over two times higher than members without DM (76.1 versus 34.5 initiators per 1,000 member-years, respectively). Statin initiation remained steady throughout 2008-2016, was slightly higher in males, and declined with increasing age. CONCLUSION: Incidence of statin use varied by CVD and DM comorbidity, and was lowest among those without CVD. These results highlight the potential clinical equipoise to conduct large pragmatic clinical trials to generate evidence that could be used to inform future blood cholesterol guidelines.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

PLoS One

DOI

EISSN

1932-6203

Publication Date

2019

Volume

14

Issue

12

Start / End Page

e0223515

Location

United States

Related Subject Headings

  • Male
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • General Science & Technology
  • Female
  • Drug Utilization
  • Diabetes Mellitus, Type 2
  • Cohort Studies
  • Cardiovascular Diseases
  • Aged, 80 and over
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Panozzo, C. A., Curtis, L. H., Marshall, J., Fine, L., Wells, B. L., Brown, J. S., … Platt, R. (2019). Incidence of statin use in older adults with and without cardiovascular disease and diabetes mellitus, January 2008- March 2018. PLoS One, 14(12), e0223515. https://doi.org/10.1371/journal.pone.0223515
Panozzo, Catherine A., Lesley H. Curtis, James Marshall, Lawrence Fine, Barbara L. Wells, Jeffrey S. Brown, Kevin Haynes, et al. “Incidence of statin use in older adults with and without cardiovascular disease and diabetes mellitus, January 2008- March 2018.PLoS One 14, no. 12 (2019): e0223515. https://doi.org/10.1371/journal.pone.0223515.
Panozzo CA, Curtis LH, Marshall J, Fine L, Wells BL, Brown JS, et al. Incidence of statin use in older adults with and without cardiovascular disease and diabetes mellitus, January 2008- March 2018. PLoS One. 2019;14(12):e0223515.
Panozzo, Catherine A., et al. “Incidence of statin use in older adults with and without cardiovascular disease and diabetes mellitus, January 2008- March 2018.PLoS One, vol. 14, no. 12, 2019, p. e0223515. Pubmed, doi:10.1371/journal.pone.0223515.
Panozzo CA, Curtis LH, Marshall J, Fine L, Wells BL, Brown JS, Haynes K, Pawloski PA, Hernandez AF, Malek S, Syat B, Platt R. Incidence of statin use in older adults with and without cardiovascular disease and diabetes mellitus, January 2008- March 2018. PLoS One. 2019;14(12):e0223515.

Published In

PLoS One

DOI

EISSN

1932-6203

Publication Date

2019

Volume

14

Issue

12

Start / End Page

e0223515

Location

United States

Related Subject Headings

  • Male
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • General Science & Technology
  • Female
  • Drug Utilization
  • Diabetes Mellitus, Type 2
  • Cohort Studies
  • Cardiovascular Diseases
  • Aged, 80 and over